Fate Therapeutics
FATE
About: Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Employees: 181
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
560% more call options, than puts
Call options by funds: $264K | Put options by funds: $40K
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
17% more capital invested
Capital invested by funds: $76.2M [Q1] → $88.8M (+$12.6M) [Q2]
13% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 40
5% more funds holding
Funds holding: 130 [Q1] → 137 (+7) [Q2]
14.75% less ownership
Funds ownership: 84.17% [Q1] → 69.42% (-14.75%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Wells Fargo
Yanan Zhu
|
$2.5
|
Equal-Weight
Maintained
|
13 Aug 2025 |
Financial journalist opinion